Serum level of M30 antigen in acute myocardial infarction

  • Yıldız Dincer
Keywords: Apoptosis, Acute Myocardial Infarction, Cytokeratin 18, M30 antigen

Abstract

Introduction: Cytokeratin 18 is a cytoskeleton protein. M30 antigen is a fragment of cytokeratin 18 which forms during apoptotic cell death and is released into circulation. The purpose of this study was to examine serum M30 antigen level as marker of apoptosis in the serum of patients with acute myocardial infarction (AMI).
Methods: Blood samples were taken on admission, on the third and seventh days of hospitalization. Serum level of M30 antigen was measured by enzyme-linked immunassay.
Results: Serum level of M30 antigen was higher in AMI patients on the admission as compared to control group (P<0.001). A time-dependent slight increase and then a reliable decrease were observed in its level during the therapy. When the patient group was divided into subgroups according to type of the reperfusion, no significant difference was found between primary PTCA group and thrombolytic therapy group for serum level of M30 antigen.
Conclusion: Serum level of M30 antigen increases in AMI patients and exhibits a time-dependent change during the therapy. Results of this preliminary study shows that M30 antigen may have the potential of to be considered as a biomarker for apoptosis in AMI.

Published
2018-04-11
Section
Original Article